Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)

NCT03519971 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03519971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03519971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2018
Completion date
March 9, 2026
Enrollment
328 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer